Charles River Laboratories Intl. Inc (CRL) Position Boosted by Guggenheim Capital LLC

Guggenheim Capital LLC lifted its holdings in Charles River Laboratories Intl. Inc (NYSE:CRL) by 17.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 139,711 shares of the medical research company’s stock after purchasing an additional 20,697 shares during the period. Guggenheim Capital LLC owned about 0.29% of Charles River Laboratories Intl. worth $14,913,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Barclays PLC increased its stake in shares of Charles River Laboratories Intl. by 184.5% in the 1st quarter. Barclays PLC now owns 54,222 shares of the medical research company’s stock valued at $5,788,000 after purchasing an additional 35,163 shares in the last quarter. United Capital Financial Advisers LLC increased its stake in shares of Charles River Laboratories Intl. by 7.6% in the 1st quarter. United Capital Financial Advisers LLC now owns 10,103 shares of the medical research company’s stock valued at $1,078,000 after purchasing an additional 717 shares in the last quarter. Blair William & Co. IL increased its stake in shares of Charles River Laboratories Intl. by 41.6% in the 1st quarter. Blair William & Co. IL now owns 2,822 shares of the medical research company’s stock valued at $301,000 after purchasing an additional 829 shares in the last quarter. Mason Street Advisors LLC increased its stake in shares of Charles River Laboratories Intl. by 2.1% in the 1st quarter. Mason Street Advisors LLC now owns 23,822 shares of the medical research company’s stock valued at $2,543,000 after purchasing an additional 488 shares in the last quarter. Finally, Northwestern Mutual Investment Management Company LLC increased its stake in shares of Charles River Laboratories Intl. by 56.5% in the 1st quarter. Northwestern Mutual Investment Management Company LLC now owns 9,705 shares of the medical research company’s stock valued at $1,036,000 after purchasing an additional 3,502 shares in the last quarter. Hedge funds and other institutional investors own 96.87% of the company’s stock.

NYSE:CRL opened at $116.21 on Monday. Charles River Laboratories Intl. Inc has a 12 month low of $94.15 and a 12 month high of $119.05. The company has a quick ratio of 1.78, a current ratio of 2.07 and a debt-to-equity ratio of 0.99. The company has a market cap of $5.57 billion, a price-to-earnings ratio of 21.64, a PEG ratio of 1.48 and a beta of 0.70.



Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings results on Thursday, May 10th. The medical research company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.12. The business had revenue of $493.97 million during the quarter, compared to analyst estimates of $480.03 million. Charles River Laboratories Intl. had a return on equity of 24.96% and a net margin of 6.78%. The business’s revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.29 earnings per share. equities research analysts forecast that Charles River Laboratories Intl. Inc will post 5.82 earnings per share for the current year.

Several brokerages recently weighed in on CRL. KeyCorp upgraded Charles River Laboratories Intl. from a “sector weight” rating to an “overweight” rating and lifted their price target for the company from $115.85 to $130.00 in a research note on Friday, June 15th. Morgan Stanley restated an “equal weight” rating and issued a $102.00 price target (up previously from $94.00) on shares of Charles River Laboratories Intl. in a research note on Wednesday, March 14th. Mitsubishi UFJ Financial Group initiated coverage on Charles River Laboratories Intl. in a research note on Friday, April 20th. They issued a “neutral” rating and a $115.00 price target for the company. Zacks Investment Research upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $117.00 price objective for the company in a research note on Friday, May 11th. Finally, TheStreet upgraded Charles River Laboratories Intl. from a “c+” rating to a “b+” rating in a research note on Thursday, May 10th. Nine research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $116.80.

In other news, Director George Massaro sold 1,218 shares of the company’s stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $107.19, for a total value of $130,557.42. Following the completion of the sale, the director now directly owns 15,055 shares in the company, valued at $1,613,745.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Ross Smith sold 945 shares of the company’s stock in a transaction that occurred on Tuesday, May 1st. The shares were sold at an average price of $104.23, for a total value of $98,497.35. Following the completion of the sale, the insider now owns 13,723 shares of the company’s stock, valued at $1,430,348.29. The disclosure for this sale can be found here. 2.10% of the stock is owned by corporate insiders.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply